Novartis pitches two new CAR-T applications to EMA; J&J reports positive data for lupus program
→ Basel-based Novartis $NVS has pushed along a double-barreled application for its leading CAR-T drug Kymriah (CTL019). The pharma giant has applied to the EMA for approvals in B-cell acute lymphoblastic leukemia as well as diffuse large B-cell lymphoma, which will likely put it head-to-head with rival Gilead’s Yescarta. “Since the historic FDA approval of Kymriah, formerly CTL019, we have launched, manufactured and supplied this highly individualized immunocelluar therapy in a commercial setting and the submission to the EMA is a major step toward our goal of delivering it to more critically ill cancer patients around the world,” said Vas Narasimhan, who’s in the process of stepping up to the CEO post.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.